Physician profile
Ted C Snodgrass
NPI 1134138795
$8,608.94
in general payments reported to CMS, 2019-2025
34 companies · $1,415 in 2025
The $1,415 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $901 · 2021: $1,606 · 2022: $1,380 · 2023: $1,218 · 2024: $1,321 · 2025: $1,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,855 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,855.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,297.85 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,193.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $907.12 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $872.61 | 2019-2025 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $718.80 | 2021-2025 | Xifaxan, Trulance |
| Abbvie INC. | $642.39 | 2021-2025 | Qulipta, Ubrelvy |
| Amarin Pharma, INC. | $442.94 | 2019-2022 | |
| Lilly USA, LLC | $435.03 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Astellas Pharma US INC | $319.86 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $264.58 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $232.20 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $227.52 | 2019-2023 | Belsomra, Lagevrio, Steglatro |
| Sanofi-Aventis U.S. LLC | $183.45 | 2019-2023 | |
| Pfizer INC. | $176.84 | 2019-2025 | |
| Abbott Laboratories | $172.06 | 2021-2025 | Freestyle Libre 3 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $61.85 | 2024-2025 | Gemtesa |
| Sanofi Pasteur INC. | $58.51 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $51.15 | 2024-2025 | Gvoke Hypopen |
| Allergan, INC. | $47.97 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.70 | 2025 | Caplyta |
| Mylan Specialty L.P. | $29.06 | 2020-2024 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $27.50 | 2022 | |
| Vanda Pharmaceuticals INC. | $25.10 | 2025 | Fanapt |
| Inspire Medical Systems, INC. | $22.75 | 2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $19.13 | 2021 | |
| Verona Pharma, INC. | $18.04 | 2025 | Ohtuvayre |
| Medtronic, INC. | $17.71 | 2025 | Intellis Adaptivestim |
| Sunovion Pharmaceuticals INC. | $17.44 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.71 | 2021 | |
| Exact Sciences Corporation | $15.54 | 2025 | The Cologuard Plus Collection Kit |
| Horizon Therapeutics Plc | $13.54 | 2019 | |
| Eisai INC. | $13.39 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.71 | 2023 | Eliquis |
| Jazz Pharmaceuticals INC. | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Snodgrass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.